Class IIOngoing

Merck Emend (aprepitant) for oral suspension recall

FDA recall D-0241-2026 · initiated Dec 12, 2025

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Presence of particulate matter: potential presence of metal particulates in the product.

Details

Product: Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured by: Novo Nordisk Production Ireland Limited Athlone, Ireland, NDC 0006-3066-03
Recalling company: Merck Sharp Dohme
Classification: Class II
Status: Ongoing
Type: Voluntary: Firm initiated
Distribution: Nationwide in the USA
Initiated: Dec 12, 2025
FDA report date: Dec 31, 2025

This recall is linked to a product we cover: Emend →

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0241-2026 ↗

← All drug recalls